Medical device company Creo Medical Group plc (AIM: CREO) on Wednesday announced the commencement of the first robotic-guided microwave ablation procedures for cancerous lung tissue at a leading UK hospital.

This follows an amendment to the company's collaboration with Intuitive, announced in July 2024, which integrates Creo's MicroBlate Flex ablation device with Intuitive's Ion Endoluminal System.

The hospital is the second UK site to perform such procedures, joining Royal Brompton Hospital, which began similar operations as part of an ongoing clinical study led by Professor Shah. The procedures are part of the Pioneer Programme, which will continue to gather clinical evidence throughout 2025 before transitioning to a commercial phase. Creo expects the number of procedures to increase within the current year.

Creo Medical specialises in developing minimally invasive electrosurgical devices for cancer treatment, including its CROMA system powered by Kamaptive technology. This advanced energy platform enables precise tissue manipulation for resection, dissection, coagulation and ablation, offering increased flexibility, precision and control in surgical procedures.